Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes.

Different from most past studies which either focused on some specific subgroups or used a small sample size, our study has observed markedly significant results among other racial/ethnic minority groups simultaneously, including American Indian/Alaska Native, Hispanic, Asian/Pacific islander groups, with 26%, 15%, 6% lower initiation rate, respectively.

also in 476 other papers